NGF for DED?
A trial using recombinant human nerve growth factor (rhNGF) eye drops to treat dry eye disease has had promising results.
Staff reporters1 min read
Advertisement
A trial using recombinant human nerve growth factor (rhNGF) eye drops to treat dry eye disease has had promising results.
Major funding from a coalition of American philanthropists is being fast-tracked to develop a simple eye test to detect early signs of Alzheimer’s disease.
Researchers at Columbia University have developed a new approach to deliver drugs safely to precise locations in the brain using ultrasound and microbubbles injected into the blood stream.The
Ophthalmologist and medical researcher Professor Bill Morgan has been appointed managing director of Lions Eye Institute.Having served as acting MD for six months, Prof Morgan was the natural choice
US researchers have been given a US$1.5million grant from the US National Institute of Health to discover if proteins in tears can predict glaucoma.
In a US$63 billion deal, US pharmaceutical company Abbvie has announced it is to takeover fellow pharma giant, Irish-based Allergan.Abbvie Chairman and CEO Richard Gonzalez will continue to lead the
Queen’s Birthday Honours have been awarded to two prominent figures in the field of eye care. Auckland-based Professor Charles McGhee has been made an Officer of the New Zealand Order of Merit for
UNICEF, the University of Papua New Guinea (PNG) and the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) have joined forces to tackle retinopathy of prematurity (ROP) in preterm babies in PNG.
Breakthroughs in healthcare can come from unusual places, said Assistant Professor Jianzhong Chen, and he and his colleagues may have discovered a new one for dry eye.
Medsafe has opened a public consultation on plans to introduce new labelling requirements for non-active substances in medicines that may cause allergic reactions. Group Manager Chris James said:
New Zealand’s first Wellbeing Budget made an ‘unprecedented investment’ in hospitals and health facilities, responding to years of under-investment by the previous government.
After struggling with supply issues due to demand levels, and last year’s batch recall, Allergan ANZ’s team has announced Ozurdex is back up to full supply for New Zealand, and has been for a few months now and, more recently, Australia.